MICROBIAL TECHNOLOGIES

Specialists in Marine Biotechnology

Biomar Microbial Technologies

Biomar is a Spanish biotechnological company

specialized in contract R&D and API discovery and production

Biomar has 29 employees in León (Spain) 75% in R&D







Milestones

1996: Spin off PharmaMar, Spanish Zeltia Group

1997: Beginning marine bio-prospecting and AQUA collection

- 1998-1999: Human Health target (Oncology)
- 2000: New target: Agriculture (Bio pesticides)
- 2001: Building production pilot plant
- 2002: Appointment of the new CEO: Dr. Antonio Fernández
- 2003. Neuro-protection and anti-angiogenesis targets
- 2004: First industrial collection of microalgae in Spain
- 2005-2006: Isolation of non-cultivable microorganisms. Expansion capital
- 2007: New target: Biodiesel
- 2008: New target: Food (preservatives)

2009: New facilities in Parque Tecnológico de León (Spain)

2010: Increasing the production capacity

2012: Approval by EPA herbicide: Thaxtomin A





Our Products

AQUA library

Production Plant



AQUA library

Three AQUA libraries

AQUA is the Library of Biomar

acua S Strain Collection **acua P** Extract Collection **acua G** Compound Collection






+120 Bioprospections looking for chemical diversity




















30% OF STRAINS ISOLATED IN BIOPROSPECTION ARE SELECTED TO AQUAS



Taxonomic criteria to avoid redundancy in the library AQUAs











AQUA Activities assayed in HEALTH CARE



MICROBIAL TECHNOLOGIES

AQUAC Pure Compounds Library




NOVEL STRUCTURE 27%







CHEMICAL NATURE OF AQUAC:



AQUA Library




Aqua S

- 66,000 strains
- 52% Actinomycetes
- 42% Fungi
- 4% Cyanobacteria
- 2% Microalgae



Aqua E

- 55,000 extracts
- 83% Marine origin
- Bioactivity data available




Aqua C

- 1754 compounds
- 892 elucidated
- 862 LCMS characterized
- 27% Novel structures



EXPERIENCE & AQUA

SCREENING APROACH





Pharmaceutical Sector

aqua G

ACTIVITY ASSAYS



STRUCTURE IDENTIFICATION



STUDIES CANDIDATES ANIMAL MODELS

BIOMAR Pipeline

OUR PIPELINE:

EARLY STAGE

Compound	Therapeutic Area	Stage
IB08C175	Multiple Sclerosis	Preclinical
IB07A037	Topic Antibiotic	Preclinical
IB10A111	Cancer (Glioblastoma)	Preclinical
IB12A157	Angiogenesis (Retinopathy)	Development





Effectiveness of Screening-Agriculture



Screening for natural herbicides, insecticides, antifungals.

Our experience is our success

Fungicides = **674** /22,228 Herbicides = **204** /22,228 Insecticides = **407** /22,228

Herbicide approved by EPA (USA)



Food Industry

Screening for discovery and development of new natural preservatives



Our experience is our success

Antibacterial = 1 /200 Novel coloring agent = 8 /21,376



Cosmetic sector

New active ingredients for Cosmetics

Our experience is our success

Skin Whitening = 5 /45,016 Antioxidant = 10/45,100 Anti-dandruff= 1 /300 Anti-acne= 1 /190



New Anti-acne agent IN-COSMETICS 2012



MORE in Biomar

PRODUCTION PLANT

Custom manufacturing Compounds in stock Compounds *on demand*





Thank you

www.biomar.co

